January 2022 in “PubMed” Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
June 2022 in “C&EN global enterprise” The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
42 citations
,
June 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
14 citations
,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
40 citations
,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
26 citations
,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
20 citations
,
January 2018 in “Expert opinion on emerging drugs” JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
2 citations
,
October 2023 in “Dermatology and therapy” Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.
2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
1 citations
,
October 2023 in “Dermatology and therapy” Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
1 citations
,
September 2023 in “Journal of drugs in dermatology” Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.
1 citations
,
August 2023 in “Acta dermato-venereologica” Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
March 2024 in “Clinical, cosmetic and investigational dermatology” Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
June 2023 in “Dermatology and therapy” Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
January 2024 in “Skin appendage disorders” Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.
52 citations
,
January 2022 in “Current Research in Pharmacology and Drug Discovery” New treatments for COVID-19 show promise, but more effective antiviral drugs are needed.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
4 citations
,
January 2023 in “Skin health and disease” Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
2 citations
,
April 2023 in “Polymers” The study created 3D-printed pills that effectively release a hair loss treatment drug over 24 hours.
1 citations
,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
August 2023 in “Dermatology and Therapy” Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.
August 2023 in “Journal of analytical & pharmaceutical research” Microneedle-assisted therapy with human basic fibroblast growth factor significantly regrew hair in patients with hair loss.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
January 2023 in “Journal of Cosmetic Dermatology”
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.